Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer b...

ver descrição completa

Detalhes bibliográficos
Autor principal: Jarimba, Roberto Saldanha (author)
Outros Autores: Eliseu, Miguel Nobre (author), Pedroso Lima, João (author), Quaresma, Vasco (author), Moreira, Pedro (author), Nunes, Pedro Coelho (author), Silva, Edgar Tavares da (author), Figueiredo, Arnaldo José (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
Texto completo:http://hdl.handle.net/10316/100893
País:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/100893

Texto Completo

http://hdl.handle.net/10316/100893

Registros relacionados